- A more rapid onset-of-action means that the newer analogue premixed insulins are more effective at lowering post-prandial rises in glucose.
- Rapid-acting analogues have a shorter duration of action than human insulin, there is a much lower risk of hypoglycaemia, especially in the hours prior to the next meal.
- In a meta-analysis, Davidson et al (2009) found that premixed insulin containing the analogue aspart was associated with 50% reduced rates of nocturnal hypoglycaemia and 65% less major hypoglycaemia than human premixed insulin.
- Unit to unit equivalent
- However, Novomix (analgoues) have a faster onset of reactions
- Ensure patients are counselled, especially on the importance of initial blood glucose monitoring following the switch and monitored for compliance and adverse events.
Premixed-Insulin as TDS Dosing
- not recommended by manufacturer or guides
- however a study on thrice daily biphasic human insulin regimen showed it is non-inferior to the basal bolus insulin analogue regimen in terms efficacy and safety in patients with poorly controlled T2DM (dose split by 40:20:40)
- Wu T (2016) Premixed insulin analogues: A new look at an established option. Diabetes & Primary Care Australia 1: 129–33
- Clinical Resource, Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes. Pharmacist’s Letter/Prescriber’s Letter. March 2017
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307189/
- http://www.gpnotebook.co.uk/simplepage.cfm?ID=x20160214160507771435
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.